<p>以超过 8000 亿美元的市值，<strong>礼来</strong>(LLY 0.70%) 是全球最大的制药公司。这在很大程度上要归功于类胰高血糖素-1(GLP-1) 激动剂的崛起，如 Mounjaro 和 Zepbound，这些产品正在为公司带来新一波增长。</p>
<p>在过去的 12 个月里，礼来的股价飙升了 58%，几乎是 <strong>标普 500 指数</strong> 和 <strong>纳斯达克综合指数</strong> 涨幅的两倍。鉴于其股价飙升，一些投资者可能认为股票分拆可能即将到来。虽然这种可能性存在，但我认为这种情况不太可能发生。自 1997 年 10 月以来，礼来就没有进行过股票分拆。</p>
<p>相反，我认为公司将会提高其股息。让我们深入了解一下礼来的股息历史，并探讨为什么我认为在年底之前可能会有一次提高。</p>
<h2>礼来的股息历史</h2>
<p>在其公司网站上，礼来的财务记录可以追溯到 1972 年。当时，礼来每股支付的季度股息仅为 0.01 美元。如今，投资者每股持有的股息为 1.30 美元（或每年 5.20 美元）。</p>
<p>尽管看到礼来在其历史上不断提高股息是件好事，但情况并非总是如此。请注意下面的图表，从 2009 年到 2014 年，礼来的股息保持不变。然而，公司从 2015 年开始稳步提高股息，这一趋势一直延续至今。</p>
<p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png"/></p>
<p>由 YCharts 提供的 LLY 股息数据</p>
<p>2015 年股息上调背后的原因之一可能是礼来的糖尿病药物 Trulicity 获得了 2014 年底美国食品和药物管理局（FDA）的批准。</p>
<p>尽管像 Zepbound 和 Mounjaro 这样的 GLP-1 药物目前是礼来最新的风向标，但公司对其癌症药物 Verzenio 的扩大适应症以及最近获得的治疗阿尔茨海默病的批准信号表明未来还有进一步增长。</p>
<p>基于这些原因，我认为礼来不仅仅是在维持其股息，而是会再次提高股息。</p>
<h2>礼来历史上何时提高股息？</h2>
<p>尽管礼来从 2015 年开始一直在稳步提高股息，但投资者应该了解一些关于这些支付时间表的细节。自那时以来，礼来每年都会在 12 月宣布提高股息支付，而除息日定在 2 月中旬。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<h2>结论</h2>
<p>虽然我不能确定礼来是否会在即将到来的 12 月再次提高股息，但历史趋势支持我的观点。如果你认为礼来将在 12 月宣布提高股息，那么你可能希望在除息日之前（可能在 2 月某个时候）购入股票。</p>
<p>礼来在 GLP-1 治疗、治疗阿尔茨海默病甚至在人工智能领域有着巨大潜力。但更重要的是，投资礼来不仅仅是投资其畅销药品。该公司为投资者提供了一个独特的价值主张，您将接触到医疗领域的几个前沿领域，同时还能获得股息。</p>
<p>我认为礼来是一个低调的 passsive income 机会，现在是购买股票的绝佳时机，无论 12 月是否再次发生股息提高。</p>

礼来

<p>礼来（LLY）是全球最大的制药公司，市值超过 2000 亿美元，其增长主要来自 GLP-1 激动剂如 Mounjaro 和 Zepbound。过去一年，其股价上涨了 58%，引发了关于股票分拆的猜测，但这被认为是不太可能的。相反，人们预计会增加股息，延续了在 12 月提高股息的历史趋势。投资者被鼓励考虑购买股票以获取 passsive income，因为礼来在包括糖尿病和阿尔茨海默病治疗在内的各个医疗领域都处于增长的位置</p>

<p>With a market capitalization of over $800 billion, <strong>Eli Lilly</strong>(LLY 0.70%) is the largest pharmaceutical company in the world. Much that is thanks to the rise of glucagon-like peptide-1 (GLP-1) agonists such as Mounjaro and Zepbound, which are fueling a new wave of growth for the company.</p>
<div class="lb-trans"><p>以超过 8000 亿美元的市值，<strong>礼来</strong>(LLY 0.70%) 是全球最大的制药公司。这在很大程度上要归功于类胰高血糖素-1(GLP-1) 激动剂的崛起，如 Mounjaro 和 Zepbound，这些产品正在为公司带来新一波增长。</p>
</div><p>Over the past 12 months, its shares have soared 58% -- nearly double the gains generated from the <strong>S&amp;P 500</strong> and <strong>Nasdaq Composite</strong>. Given its soaring share price, some investors might think a stock split could be on the horizon. While this is possible, I see it as unlikely. Lilly hasn't split its stock since October 1997.</p>
<div class="lb-trans"><p>在过去的 12 个月里，礼来的股价飙升了 58%，几乎是 <strong>标普 500 指数</strong> 和 <strong>纳斯达克综合指数</strong> 涨幅的两倍。鉴于其股价飙升，一些投资者可能认为股票分拆可能即将到来。虽然这种可能性存在，但我认为这种情况不太可能发生。自 1997 年 10 月以来，礼来就没有进行过股票分拆。</p>
</div><p>Instead, I think the company is going to raise its dividend. Let's dig into Lilly's dividend history, and explore why I think a raise could come before year-end.</p>
<div class="lb-trans"><p>相反，我认为公司将会提高其股息。让我们深入了解一下礼来的股息历史，并探讨为什么我认为在年底之前可能会有一次提高。</p>
</div><h2>Eli Lilly's dividend history</h2>
<div class="lb-trans"><h2>礼来的股息历史</h2>
</div><p>On its corporate website, Eli Lilly's financial records date back to 1972. Back then, Lilly paid a modest quarterly dividend of just $0.01 per share. Today, investors receive quarterly dividend payments of $1.30 (or $5.20 per year) for each share they own.</p>
<div class="lb-trans"><p>在其公司网站上，礼来的财务记录可以追溯到 1972 年。当时，礼来每股支付的季度股息仅为 0.01 美元。如今，投资者每股持有的股息为 1.30 美元（或每年 5.20 美元）。</p>
</div><p>While it's nice to see that Lilly has raised its dividend throughout its history, that hasn't always been the case. Note in the graph below how between 2009 and 2014 Lilly's dividend stayed flat. However, the company began to steadily raise its dividend starting in 2015, and this is a theme that has remained to today.</p>
<div class="lb-trans"><p>尽管看到礼来在其历史上不断提高股息是件好事，但情况并非总是如此。请注意下面的图表，从 2009 年到 2014 年，礼来的股息保持不变。然而，公司从 2015 年开始稳步提高股息，这一趋势一直延续至今。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png" alt="" original-src="https://media.ycharts.com/charts/a49ddf68012adcc94b68f8bff4fd858c.png"/></p>
<p>LLY Dividend data by YCharts</p>
<div class="lb-trans"><p>由 YCharts 提供的 LLY 股息数据</p>
</div><p>One of the reasons behind the dividend hike in 2015 could have been the approval of Lilly's diabetes medication Trulicity, which got the nod from the Food and Drug Administration (FDA) in late 2014.</p>
<div class="lb-trans"><p>2015 年股息上调背后的原因之一可能是礼来的糖尿病药物 Trulicity 获得了 2014 年底美国食品和药物管理局（FDA）的批准。</p>
</div><p>While GLP-1 medicines such as Zepbound and Mounjaro are currently Lilly's newest bellwethers, the company's expanded indication for its cancer drug, Verzenio, plus its recent approval for its Alzheimer's treatment signal further growth ahead.</p>
<div class="lb-trans"><p>尽管像 Zepbound 和 Mounjaro 这样的 GLP-1 药物目前是礼来最新的风向标，但公司对其癌症药物 Verzenio 的扩大适应症以及最近获得的治疗阿尔茨海默病的批准信号表明未来还有进一步增长。</p>
</div><p>For these reasons, I think Lilly is positioned for more than just maintaining its dividend, but raising it again.</p>
<div class="lb-trans"><p>基于这些原因，我认为礼来不仅仅是在维持其股息，而是会再次提高股息。</p>
</div><h2>When does Elil Lilly historically raise its dividend?</h2>
<div class="lb-trans"><h2>礼来历史上何时提高股息？</h2>
</div><p>Although Lilly started consistently raising its dividend in 2015, investors should be aware of some details around the schedule of these payments. Every year since then, Lilly announced a hike to its dividend payment in December with an ex-dividend date slotted for mid-February.</p>
<div class="lb-trans"><p>尽管礼来从 2015 年开始一直在稳步提高股息，但投资者应该了解一些关于这些支付时间表的细节。自那时以来，礼来每年都会在 12 月宣布提高股息支付，而除息日定在 2 月中旬。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy83OTExMzkvZ2V0dHlpbWFnZXMtMTkyNDc2NTkxMS5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F791139%2Fgettyimages-1924765911.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>The bottom line</h2>
<div class="lb-trans"><h2>结论</h2>
</div><p>While I can't say for certain that Lilly will raise its dividend again this upcoming December, historical trends are on my side. If you do think Lilly is going to announce a dividend hike in December, then you may want to scoop up shares before the ex-dividend date (likely to be sometime in February).</p>
<div class="lb-trans"><p>虽然我不能确定礼来是否会在即将到来的 12 月再次提高股息，但历史趋势支持我的观点。如果你认为礼来将在 12 月宣布提高股息，那么你可能希望在除息日之前（可能在 2 月某个时候）购入股票。</p>
</div><p>Lilly has enormous potential between GLP-1 treatments, treating Alzheimer's disease, and even longer-term bets in artificial intelligence. But the bigger idea here is that there is more to investing in Lilly than just its blockbuster drugs. The company offers investors a unique value proposition in that you're exposed to several cutting-edge areas in the healthcare realm, while also collecting a dividend.</p>
<div class="lb-trans"><p>礼来在 GLP-1 治疗、治疗阿尔茨海默病甚至在人工智能领域有着巨大潜力。但更重要的是，投资礼来不仅仅是投资其畅销药品。该公司为投资者提供了一个独特的价值主张，您将接触到医疗领域的几个前沿领域，同时还能获得股息。</p>
</div><p>I see Lilly as an under-the-radar passive income opportunity and think now is as good a time as ever to buy shares, whether a dividend hike occurs again in December or not.</p>
<div class="lb-trans"><p>我认为礼来是一个低调的 passsive income 机会，现在是购买股票的绝佳时机，无论 12 月是否再次发生股息提高。</p>
</div>

预测：礼来股票接下来的走势（提示：不是股票拆分）